MARKET

XENE

XENE

Xenon Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.40
-0.05
-0.29%
Closed 16:00 01/17 EST
OPEN
17.59
PREV CLOSE
17.45
HIGH
18.10
LOW
17.15
VOLUME
201.18K
TURNOVER
--
52 WEEK HIGH
18.10
52 WEEK LOW
7.55
MARKET CAP
450.12M
P/E (TTM)
-11.9859
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of XENE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

XENE News

  • The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares
  • Benzinga.2d ago
  • Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update
  • GlobeNewswire.6d ago
  • Will Xenon Continue to Surge Higher?
  • Zacks.01/10 13:08
  • The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx
  • Benzinga.01/10 12:13

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About XENE

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.
More

Webull offers Xenon Pharmaceuticals Inc (XENE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.